GlassScriptPhysician profile
Abigail Masters
NPI 1881221893
$1,699.24
in general payments reported to CMS, 2019-2025
23 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $144 · 2023: $333 · 2024: $470 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.97 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $265.12 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $166.43 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.60 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $161.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $159.49 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $131.74 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.24 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $90.57 | 2021-2025 | Pediarix, Bexsero, Penmenvy |
| Sumitomo Pharma America, INC. | $64.52 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $63.89 | 2021-2025 | Trintellix |
| Corium, LLC | $61.17 | 2024-2025 | Azstarys |
| Dexcom, INC. | $43.30 | 2021-2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $41.18 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $33.95 | 2024-2025 | Auvelity |
| Amarin Pharma, INC. | $31.29 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $20.37 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $17.80 | 2025 | |
| Exact Sciences Corporation | $16.91 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $16.63 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.95 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $15.82 | 2024 | |
| Merck Sharp & Dohme LLC | $15.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.